Despite their potential, there are challenges in utilizing TILs for cancer treatment. Not all tumors naturally have a high infiltration of lymphocytes, and some tumors may create an immunosuppressive environment that renders TILs ineffective. Additionally, expanding TILs ex vivo and ensuring their survival and function upon reinfusion can be technically challenging and resource-intensive.
